Brian and I got married two years ago. At that time I went through all of our finances, combined accounts, changed names, updated beneficiaries, and made a list of items to complete: wills, powers of attorney and additional life insurance for me.
That was September 2011. While our finances are doing fine, our estate plan is only partially completed.
Time got away from me, as it does with all of us sometimes. We both completed the forms required by the military to get our wills done, but then I needed to be present to execute mine and since it was hard for me to get away from the office during the week, Brian got his copy completed before he deployed earlier this year, while my completed draft gathered dust on our desk and is now outdated and needs to be redone.
Hot India Companies To Buy For 2015: UC Resources Ltd (UC&C)
UC Resources Ltd. is an exploration-stage company. The Company is engaged principally in the acquisition, exploration and development of mineral properties in Mexico. The Company focuses on silver and gold exploration and production in Mexico. Its mineral properties include Copalquin property (Copalquin Project) and La Yesca. Its Copalquin is located in the northwestern state corner of Durango State, in Mexico. La Yesca is 100% owned by the Company�� subsidiary, Minera Silver Creeck. The La Yesca milling project is located near the town of La Yesca in Nayarit, Mexico, approximately 100 kilometers northwest of Guadalajara City. In the La Yesca district there are at least 16 known gold and silver mineral discoveries. The Mar project consists of a 100 hectare mining exploitation concession. On September 6, 2012, the Company discovered another previously unknown existing mine prospect on the La Yesca property just North of La Leona Mine. Advisors' Opinion:- [By Victor Selva]
Polycom provides standards-based unified communications and collaboration (UC&C) solutions for voice and video collaboration. The company has three products and solutions categorized as follows: UC Platform, UC Group Systems and UC Personal Devices.
Hot Forestry Companies To Invest In Right Now: Micromem Technologies Inc (MMTIF)
Micromem Technologies Inc. (Micromem), incorporated on October 21, 1985, is a development-stage company. The Company is engaged in the development of memory technology that has the characteristics of non-volatility, which is the ability to retain information after power has been shut off. The Company is focused on magnetic sensor applications. The Company is focused on research and development of nano-magnetic random access memory (MRAM). Micromem operates in a single segment as a developer of non-volatile magnetic memory and sensor technology. The Company partners with industry to manufacture.
The Company�� technology is based on the ability to use magnetic materials in combination with a sensor to record the state of magnetization. Each magnetic element stores one bit of data based on its ability to alternate between states of magnetic polarization, which states are determined by a sensor.
The Company competes with IBM.
Advisors' Opinion:- [By Peter Graham]
At the end of last week, small cap stocks Senesco Technologies, Inc (OTCBB: SNTI), VolitionRX Ltd (OTCMKTS: VNRX) and Micromem Technologies Inc (OTCBB: MMTIF) were all trending upwards ��ending up 13.65%, 8.73% and 7.61%, respectively, on Friday. However, it�� a new trading week with the last two trading days for the year. So what direction will these three small caps head in for the end of this year and into next year? Here is a quick look to help you decide on a trading or investment strategy:
Hot Forestry Companies To Invest In Right Now: Gevo Inc (GEVO)
Gevo, Inc., incorporated in June 2005, is a renewable chemicals and advanced biofuels company. The Company is focused on the development and commercialization of alternatives to petroleum-based products. The Company operates in two segments: Gevo, Inc. Segment and Gevo Development/Agri-Energy Segment. Gevo, Inc. Segment is responsible for all research and development activities related to the future production of isobutanol, maintaining and protecting its intellectual property portfolio, developing future markets for its isobutanol and providing corporate oversight services. Its Gevo Development/Agri-Energy Segment is responsible for the production of ethanol and related products. In September 2010, the Company acquired a 22 MGPY ethanol production facility in Luverne, Minnesota that the Company intends to retrofit to produce isobutanol.
The Company�� isobutanol can also be converted by its customers into a range of hydrocarbons, which form the basis for the production of many products, including plastics, fibers, rubber and other polymers and hydrocarbon fuels, including jet and diesel fuel. Its technology platform consists of biocatalysts and a isobutanol separation unit. Together these technologies form the Gevo Integrated Fermentation Technology (GIFT). GIFT is designed to allow relatively low capital expenditure retrofits of existing ethanol facilities, enabling isobutanol production from a range of renewable feedstocks. The Company�� biocatalysts are microorganisms that have been designed to metabolize sugars to produce isobutanol.
GIFT consists of two components, biocatalysts which convert sugars derived from multiple renewable feedstocks into isobutanol through fermentation, and a separation unit which is designed to continuously separate isobutanol from water during the fermentation process. The Company developed its technology platform to be compatible with the existing approximately 20 BGPY of global operating ethanol production capacity, as estimated by the R! enewable Fuels Association (RFA).
The Company competes with Butamax Advanced Biofuels LLC (Butamax), BP p.l.c. (BP), E. I. du Pont de Nemours and Company, Butalco GmbH, Cathay Industrial Biotech Ltd., METabolic EXplorer S.A., TetraVitae Bioscience, Inc., Cobalt Technologies, Inc., Green Biologics Ltd. Shell Oil Products US (Shell Oil), BP, DuPont-Danisco Cellulosic Ethanol LLC, Abengoa Bioenergy, S.A., POET, LLC, ICM, Mascoma, Range Fuels, Inbicon A/S, INEOS New Planet BioEnergy LLC, Coskata, Archer Daniels Midland Company, BlueFire Ethanol, Inc., KL Energy Corporation, ZeaChem Inc., Iogen Corporation, Qteros, Inc., and AE Biofuels, Inc.
Advisors' Opinion:- [By Bryan Murphy]
It was already hanging by a thread, and then only because it bounced back from an early-November plunge. But, with the action we've seen from Gevo, Inc. (NASDAQ:GEVO) since that now-failed recovery effort, it's pretty safe to say GEVO is beyond help/hope, if it falls under one more big line in the sand.... and it's looking like it's only a matter of time before that happens.
- [By Maxx Chatsko]
I imagine the company has made headway since its initial press release, especially with commissioning for its Moema, Brazil, biorefinery looming. When updates are given on commercial achievements in the months ahead, will you be able to digest the important information that affects your investments? Heading into the homestretch of the first wave of commercial buildout, it is crucially important to understand what Solazyme, Gevo (NASDAQ: GEVO ) , and�Amyris� (NASDAQ: AMRS ) spill in press releases -- and the greater detail given in SEC filings.
- [By Alyce Lomax]
Solazyme is more than a biofuels play like fellow biofuels upstarts like Amyris (NASDAQ: AMRS ) and Gevo (NASDAQ: GEVO ) . I purchased shares of Solazyme for the Prosocial Portfolio (I hold shares in my personal portfolio, too) not only for its impressive foray into a nascent field, but also because it had already inked some impressive partnerships. Meanwhile, its alternative oils go much further than simply trying to provide alternatives to fossil fuels. Its microalgae-derived oils can also be used in skin care and food.
- [By John Udovich]
Small cap biofuel or synthetic fuel stocks Gevo, Inc (NASDAQ: GEVO), KiOR Inc (NASDAQ: KIOR), Solazyme Inc (NASDAQ: SZYM) and Syntroleum Corp (NASDAQ: SYNM) all seem to have been seeing some trading action in recent days���meaning its worth taking a closer look at all four�before taking a look at their rather dismal�long term performance while noting that none are yet profitable:
Hot Forestry Companies To Invest In Right Now: Interleukin Genetics Inc (ILIU.PK)
Interleukin Genetics, Inc., incorporated on March 28, 2000, is a personalized health company, which develops genetic tests to provide information to manage health and specific health risks. The Company�� business focuses on personalized health, by providing genetic tests with clinical value. Its tests are made available through marketing partners or directly to end users. The Company's primary business focus and strategy is to continue the Company's commercialization efforts with its PST genetic test. In addition, the Company plans to continue to develop and sells tests for its own business needs under the Inherent Health brand.
The Company's genetic tests that are being commercialized includes PST is a genetic test, which analyzes genetic variations associated with inflammation and identifies individuals who are at increased risk for more severe periodontal disease; Weight Management Genetic Test determines whether a low fat, low carbohydrate or balanced diet may normal or vigorous exercise, which is needed to lose existing body fat; Bone Health Genetic Test is designed to identify whether an individual is more likely to be susceptible to spine fractures and low bone mineral density associated with osteoporosis; Heart Health Genetic Test is designed to identify genetic predisposition to excess inflammation, which is a risk factor for heart attack, and Wellness Select Genetic Test allows buyers to purchase any combination of Inherent Health genetic tests at a discounted price. The Company is also focusing its genetic test development efforts on the development of an Osteoarthritis, or OA, genetic test to identify individuals at increased risk for severe OA.
Genetic Test for Risk of Periodontal Disease
PST is a genetic test that analyzes genetic variations associated with inflammation and identifies individuals who are at increased risk for more severe periodontal disease. The PST genetic test identifies specific polymorphisms (genetic variations) in genes that! regulate the production of interleukin cytokines.Interleukin-1 (IL-1) is well-established as one of the critical regulators of periodontal disease, and studies in non-human primates have shown that drugs specifically blocking IL-1 alone or IL-1 plus TNFa reduces tissue destruction even when the bacterial challenge is not reduced.
Inherent Health Brand of Genetic Tests
The Company's Weight Management Genetic Test helps take the guesswork out of finding an effective diet and exercise solution by revealing actionable steps to achieve weight goals based on genetics. The test provides new information beyond traditional assessments, so that nutritional intake and fitness routines can be tailored for improved, sustainable results. This test identifies five SNPs in four human genes: fatty acid binding protein 2 (FABP2); adrenergic receptor beta 2 (ADRB2 two variations); adrenergic receptor beta 3 (ADRB3); and peroxisome proliferator-activated receptor gamma (PPAR- ). These markers are involved in certain physiological pathways relating to body weight. Certain patterns of markers are associated with differential response to certain diet and exercise regimens.
The Company has conducted a number of studies that demonstrate a gene-diet interaction based on the multi-locus patterns . In the original study, 311 overweight/obese (body mass index, 27-40 kg/m2), nondiabetic, premenopausal, generally healthy women were randomly assigned for 12 months to either the Atkins-like ( low carbohydrate), Zone-like (low carbohydrate), LEARN-like (balanced), or Ornish-like (low fat) diets for the primary purpose of losing weight. The data collected in that study included dietary intake assessment (three unannounced 24-hour recalls for each time point administered by a dietitian and analyzed using NDS-R, University of Minnesota), anthropometric measures including weight, and related physiological variables, all collected at baseline, two, six, and 12 months.
Bone Health Genetic T! est
The Company's Bone Health Genetic Test is designed to identify whether an individual is more likely to be susceptible to spine fractures and low bone mineral density associated with osteoporosis. Although it typically starts later in life, early intervention can help prevent osteoporosis. Preventive measures can reduce the risk for bone loss and fractures, which in the case of vertebral fractures leads to a hunched over appearance. The test identifies a SNP in each of three genes involved in processes that affect bone; estrogen receptor alpha (ER1 Xba1), vitamin D receptor (VDR), and interleukin-1 (IL-1). Certain patterns of variations are associated with increased risk of spine fracture and/or low bone mineral density. The test can be used as an aid to making diet, exercise, and other lifestyle choices to maintain and improve bone health.
Nutritional Needs Genetics Test
The Company's Nutritional Needs Genetics Test is designed to identify DNA variations in genes crucial to B-vitamin metabolism and the ability to manage oxidative stress. Individuals with certain variations in these genes may be at increased risk for ineffective utilization of B-vitamins and potential for cell damage caused by oxidative stress, both of which can in some cases lead to increased risk for certain diseases. The test identifies the presence or absence of human genotypic markers methylenetetrahydrofolate reductase (MTHFR) and transcobalamin II (TCN2) involved in vitamin B metabolism and markers superoxide dismutase 2 (SOD2), glutathione S-transferase 1 deletions (GSTM1), paraoxonase 1 (PON1), X-ray repair cross complementing group 1 (XRCC1) in response to oxidative stress. Certain variations are associated with less efficient B-vitamin metabolism or reduced activity of endogenous anti-oxidant systems. The test may be used to aid individuals in deciding whether to supplement their diet with B vitamins and/or antioxidants.
Genetic Test Pipeline
The Company is focusing! its gene! tic test development efforts on programs, including Osteoarthritis Genetic Test. OA is the common adult joint disease, increasing in frequency and severity in all aging populations. The estimated U.S. prevalence is 20-40 million patients or five times that of rheumatoid arthritis. The Company's OA program plans to investigate whether interleukin gene variations together with several other inflammatory gene variations is associated with the occurrence of multi-joint OA for the development of a genetic risk assessment test.
Advisors' Opinion:- [By Brian Marckx]
Interleukin Genetics, Inc. (ILIU.PK) develops genetic tests focused on personal health. Through applied genetics research and scientific collaborations, the company has made significant progress in understanding how genetic make-up can affect an individual's predisposition and risk of suffering from certain diseases. Interleukin's research has specifically focused on a form of genetic variation called single nucleotide polymorphisms (SNP) and how it can have an impact on a person's health. The company has applied this knowledge in the development of genetic tests focused on areas such as weight management, cardiovascular health and periodontal disease. Interleukin sells its Inherent Health line of tests, which launched in 2009, to the consumer market and maintains a CLIA-certified lab at its headquarters in Waltham, Massachusetts, where consumers send test samples for processing.
No comments:
Post a Comment